Traders bought shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading on Tuesday. $119.62 million flowed into the stock on the tick-up and $55.66 million flowed out of the stock on the tick-down, for a money net flow of $63.96 million into the stock. Of all stocks tracked, Becton, Dickinson and had the 11th highest net in-flow for the day. Becton, Dickinson and traded down ($0.93) for the day and closed at $221.27

Several equities research analysts recently commented on the company. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Tuesday, October 31st. Cowen and Company reiterated a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reiterated an “equal weight” rating and set a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $230.00 target price (up from $210.00) on shares of Becton, Dickinson and in a report on Friday. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $213.47.

The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. The firm has a market capitalization of $50,250.00, a P/E ratio of 23.65, a price-to-earnings-growth ratio of 1.78 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same quarter last year, the firm earned $2.12 EPS. Becton, Dickinson and’s quarterly revenue was down 2.0% on a year-over-year basis. sell-side analysts predict that Becton, Dickinson and Company will post 10.6 earnings per share for the current year.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares in the last quarter. Koch Industries Inc. raised its stake in Becton, Dickinson and by 45,268.7% during the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after acquiring an additional 1,395,182 shares in the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC bought a new stake in Becton, Dickinson and during the 2nd quarter valued at $225,164,000. Finally, Janus Henderson Group PLC raised its stake in Becton, Dickinson and by 1,265.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after acquiring an additional 1,122,191 shares in the last quarter. Institutional investors and hedge funds own 86.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Traders Buy Becton, Dickinson and Company (BDX) on Weakness” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/07/traders-buy-becton-dickinson-and-company-bdx-on-weakness.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.